Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci

Human Genetics

Volumn 102, Issue 5, 1998, Pages 526-532

  Muiras, Marie Laure ^b   Verasdonck, Patrick ^a   Cottet, Florence ^a   Schächter, Franu̧ois ^a  

^a FONDATION JEAN DAUSSET CEPH   (France)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE;

AGED; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LONGEVITY; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; FEMALE; GENE DELETION; GLUTATHIONE TRANSFERASE; HUMANS; LONGEVITY; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 0031799019     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004390050735     Document Type: Article

References (48)

1. Abbot MH, Murphy EA, Boiling DR, Abbey H (1974) The familial component in longevity, a study of the offspring of nonagenarians II. Preliminary analysis of the complete study. Johns Hopkins Med J 134:1-16
2. Agundez JAG, Jimenez-Jimenez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L, Vazquez A, Parra J, Duare J, Coria F, Ladero JM, Alvarez JC, Benitez J (1995) Association between oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 57:291-298
3. Agundez JAG, Menaya JG, Tejeda R, Lago F, Chavez M, Benitez J (1996) Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. Pharmacogenetics 6:465-472
4. Agundez JAG, Rodriguez I, Olivera M, Ladero JM, Garcia MA, Ribera JM, Benitez J (1997) CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing 26:147-151
5. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169-170
6. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubae EF, Lucier GW (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow acetylator allele common in African-Americans. Carcinogenesis 14:1689-1692
7. Bordet R, Broly F, Destée A, Libersa C, Lafitte JJ (1996) Lack of relationship between genetic polymorphism of cytochrome p450IID6 and sporadic idiopathic Parkinson's disease. Clin Neuropharmacol 19:213-221
8. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I (1993) Genotype and phenotype of glutathione 5-transferase class μ isoenzymes μ and y in lung cancer patients and controls. Cancer Res 53:1004-1011
9. Bulowvskaya LN, Krupin RG, Bochina TA, Shipova AA, Pavlova MV (1978) Acetylator phenotype in patients with breast cancer. Oncology 35:185-188
10. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842-845
11. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57; 581-592
12. Cholerton S, Daly AK, Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434-438
13. Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle JR (1993) Homozygous deletion of the gene for glutathione S-transferase M1 in bladder cancer Br Med J 307:481-482
14. Daly AK, Cholerton S, Armstrong M, Iddle JR (1994) Genotyping for polymorphism in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 102:55-61
15. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenesis 6:193-201
16. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, White R (1990) Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics 6:575-577
17. Heagerty AHM, Fitzgerald D, Smith A, Bowers B, Jones P, Fryer AA, Zhao L, Alldersea J, Strange RC (1994) Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 343:266-268
18. Hickman D, Sim E (1991) N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 42:1007-1014
19. Hirvonen A (1995) Genetic factors in individual responses to environmental exposures. J Occup Environ Med 37 :37-43
20. Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K (1995) Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 55:2981-2983
21. Johnson TE (1997) Genetic influences on aging. Exp Gerontol 32:11-22
22. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF (1992) The human glutathione S-transferase supergene family, its polymorphism and its effects on susceptibility to lung cancer. Environ Health Perspect 98:87-94
23. Korrapati MR, Sorkin JD, Andres R, Muller DC, Loi C, Vessel ES, Vestal RE (1997) Acetylator phenotype in relation to age and gender in the Baltimore longitudinal study of aging. J Clin Pharmacol 37:83-91
24. Laurent-Kenesi MA, Jacqz-Aigrain E, Lejonc JL, Jaillon P, Funck-Brentano C (1996) Assessment of CYP2D6 activity in very elderly healthy subjects. Fundam Clin Pharmacol 10:159
25. Lin HJ, Han C, Lin BK, Hardy S (1994) Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene Pharmacogenetics 4:1 25-134
26. Lucotte G, Turpin JC, Gerard N, Panserat S, Krishnamoorthy R (1996) Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families. Am J Med Genet 67:361-365
27. Mannervik B, Awasthi YC, Board PG, Hayes JD, Di Ilio C, Ketterer B, Listowsky I, Morgenstern R, Muramatsu M, Pearson WP, Pickett CB, Sato K, Widersten M, Wolf CR (1992) Nomenclature for human glutathione transferases. Biochem J 282:305-308
28. McLaren EH, Burden AC, Moorhead PJ (1977) Acetylator phenotype in diabetic neuropathy. Br Med J 2:291-293
29. Mrozikiewicz PM, Drakoulis N, Roots I (1994) Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 56:626-634
30. Olshansky SJ, Carnes BA, Cassel C (1990) In search of Methuselah: estimating the upper limits to human longevity. Science 250:634-640
31. Pearson WR, Vorachek WR, Xu S, Berger R, Hart I, Vannais D, Patterson D (1993) Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome Ip13. Am J Hum Genet: 53:220-233
32. Pirmohamed M, Wild MJ, Kitteringham NR, O'Brien K, Buchan IE, Back DJ, Park BK (1996) Lack of association between schizophrenia and the CYP2D6 gene polymorphisms. Am J Med Genet 67:236-237
33. Poirier J, Roy M, Campanella G, Cloutier T, Paris S (1987) Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet 2:386
34. Proust J, Moulias R, Fumeron F, Bekkhoucha F, Busson M, Schmid M, Hors J (1982) HLA and longevity. Tissue Antigens 19:168-173
35. Rattan SIS (1995) Ageing - a biological perspective. Mol Aspects Med 16:439-508
36. Sachse C, Brockmöller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
37. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
38. Schächter F, Cohen D, Kirkwood TBL (1993) Prospects for the genetics of human longevity. Hum Genet 91:519-526
39. Schächter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6:29-32
40. Seidegard J, Vorachek WR, Pero RW, Pearson WR (1988) Hereditary differences in the expression of the human glutathione S-transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297
41. Siegmund W, Hanke W, Zschiesche M, Franke G, Biebler KE, Wilke A (1990) N-Acetylation and debrisoquine-type oxidation polymorphism in Caucasians with reference to age and sex. Int J Clin Pharmacol Ther 28:504-509
42. Slagboom PE, Knock DL (1996) Genetics of ageing and multifactorial diseases. In: Rattan SIS, Toussaint O (eds) Molecular gerontology: research status and strategies. Plenum Press, New York, pp 1-14
43. Smith CAD, Cough AC, Leigh NP, Summers BA, Harding AE, Maranganore DM, Sturman SG, Schapira AHV, Williams AC, Spurr NG, Wolf CR (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377
44. Takata H, Ishii T, Suzuki M, Sekiguchi S, Iri H (1987) Influence of major histocompatibility complex region genes on human longevity among Okinawan Japanese centenarians and nonagenarians. Lancet II: 824-826
45. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Price Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17
46. Wolf CR, Smith CAD, Gough AC, Moss JE, Valus KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spun NK (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13:1035-1038
47. Zhong S, Spurr NK, Hayesh JD, Wolf CR (1993a) Deduced amino acid sequence, gene structure and chromosomal location of a novel class μ glutathione S-transferase, GSTM4. Biochem J 291:41-50
48. Zhong S, Wyllie H, Barnes D, Wolf CR, Spurr NK (1993b) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis: 14:1821-1824